

Individualised Cancer Vaccines: Developing a High-throughput cGMP Peptide Manufacturing Philosophy

Alaric Desmarchelier

Almac Group

In the field of personalised cancer treatments, neoantigen-derived peptides are one of the key modalities in the current arsenal to tackle difficult tumours. Each patient receives a cocktail of active pharmaceutical ingredients tailored to their unique tumour, helping their immune system combat cancer. However, traditional approaches to manufacturing, analytical, and regulatory aspects of drug development are ill-suited for this world – every patient receives a different drug! As pioneer manufacturers in the high-throughput production of peptides for personalised cancer vaccines, we propose a unique insight into this fascinating world through a short summary of our journey so far.